Attached files

file filename
EX-31 - DNA Systems, Inc.exhibit322.htm
EX-32 - DNA Systems, Inc.exhibit312.htm
EX-31 - DNA Systems, Inc.exhibit311.htm
EX-32 - DNA Systems, Inc.exhibit321.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended October 31, 2009


[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from ___________ to ______________


Commission File Number: 333-152679


DNA SYSTEMS, INC.

 (Exact name of registrant as specified in its charter)


Nevada

 

98-0557273

(State or other jurisdiction of incorporation)

 

(IRS Employer Identification Number)

 

Rm 2213-14, 22nd Floor,

Jardine House, 1 Connaught Place,

Central, Hong Kong

(Address of principal executive offices)

(852) 2802-8663

(Registrant’s telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  [ X ] Yes   [ ] No


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Not Applicable.


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer [ ]

Accelerated filer [ ]

Non-accelerated filer [ ]  (Do not check if a smaller reporting company)

Smaller reporting company [ X ]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ X ] Yes   [ ] No


As of December 15, 2009, there were 8,500,000 shares of voting common stock, $0.001 par value, of DNA Systems, Inc. issued and outstanding.


- 1 -



PART I – FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS


The financial statements of DNA Systems, Inc. (“we”, “us”, “our”, “DNAS” or the “Company”) a Nevada corporation, included herein were prepared, without audit, pursuant to rules and regulations of the Securities and Exchange Commission.  Because certain information and notes normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America were condensed or omitted pursuant to such rules and regulations, these financial statements should be read in conjunction with the financial statements and notes thereto included in the audited financial statements of the DNA Systems, Inc., for the fiscal year ended April 30, 2009 included in the Company’s Form 10K filed with the Securities and Exchange Commission on July 29, 2009.



DNA SYSTEMS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008





INDEX






Page


Condensed balance sheets

3


Condensed statements of operations and comprehensive loss

4


Condensed statements of cash flows

5


Notes to condensed financial statements

6 - 13















- 2 -



DNA SYSTEMS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED BALANCE SHEETS

AS OF OCTOBER 31, 2009 AND APRIL 30, 2009





 

As of

 

 

As of

 

 

October 31,

 

 

April 30,

 

 

2009

 

 

2009

 

 

(Unaudited)

 

 

 

 

 

US$

 

 

US$

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

681

 

 

818

 

 

 

 

 

 

 

Total assets

681

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIT

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

Accrued audit fee

4,152

 

 

5,754

 

Amount due to a stockholder (Note 7)

95,886

 

 

26,741

 

 

 

 

 

 

 

Total liabilities

100,038

 

 

 

 

 

 

 

 

 

 

Stockholders’ deficit

 

 

 

 

 

Common stock - US$0.001 par value (Note 4)

 

 

 

 

 

Authorized 65,000,000 shares; 8,500,000

 

 

 

 

 

shares issued and outstanding

8,500

 

 

8,500

 

Accumulated deficit during the development stage

(109,001

)

 

(40,090

)

Accumulated other comprehensive income (loss)

1,144

 

 

(87

)

 

 

 

 

 

 

Total stockholders’ deficit

(99,357

)

 

(31,677

)

 

 

 

 

 

 

Total liabilities and stockholders’ deficit

681

 

 

818

 





See accompanying notes to condensed financial statements.



- 3 -



DNA SYSTEMS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





 

Three months

 

Six months

 

 

Cumulative

 

 

ended October 31,

 

ended October 31,

 

 

total since

 

 

2009

 

2008

 

2009

 

2008

 

 

inception

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

 

(Unaudited)

 

 

US$

 

US$

 

US$

 

US$

 

 

US$

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

-

 

-

 

-

 

6,407

 

 

6,407

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

Formation expenses

-

 

-

 

-

 

-

 

 

513

 

General and administrative expenses

22,982

 

8,986

 

68,911

 

16,316

 

 

114,895

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income taxes

(22,982

)

(8,986

)

(68,911

)

(9,909

)

 

(109,001

)

Income taxes (Note 2)

-

 

-

 

-

 

-

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

(22,982

)

(8,986

)

(68,911

)

(9,909

)

 

(109,001

)

Other comprehensive (loss) income

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

(1

)

(1

)

1,231

 

(5

)

 

1,144

 

 

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive loss

(22,983

)

(8,987

)

(67,680

)

(9,914

)

 

(107,857

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share :

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted (Note 3)

(0.00

)

(0.00

)

(0.01

)

(0.00

)

 

(0.01

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares :

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

8,500,000

 

8,500,000

 

8,500,000

 

8,500,000

 

 

8,004,071

 





See accompanying notes to condensed financial statements.



- 4 -



DNA SYSTEMS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED STATEMENTS OF CASH FLOWS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





 

Three months

 

Six months

 

 

Cumulative

 

 

ended October 31,

 

ended October 31,

 

 

total since

 

 

2009

 

2008

 

2009

 

2008

 

 

inception

 

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

(Unaudited)

 

 

(Unaudited)

 

 

US$

 

US$

 

US$

 

US$

 

 

US$

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

 

 

 

Net loss

(22,982

)

(8,986

)

(68,911

)

(9,909

)

 

(109,001

)

Change in liability

 

 

 

 

 

 

 

 

 

 

 

Accrued audit fee

(364

)

(4,520

)

(1,602

)

(856

)

 

4,152

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

(23,346

)

(13,506

)

(70,513

)

(10,765

)

 

(104,849

)

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of

 

 

 

 

 

 

 

 

 

 

 

common stock

-

 

-

 

-

 

-

 

 

8,500

 

Advances from a stockholder

23,288

 

4,389

 

69,145

 

4,389

 

 

95,886

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

23,288

 

4,389

 

69,145

 

4,389

 

 

104,386

 

 

 

 

 

 

 

 

 

 

 

 

 

Effect of foreign exchange rate changes in

 

 

 

 

 

 

 

 

 

 

 

  cash and cash equivalents

(1

)

(1

)

1,231

 

(5

)

 

1,144

 

 

 

 

 

 

 

 

 

 

 

 

 

Net change in cash and cash equivalents

(59

)

(9,118

)

(137

)

(6,381

)

 

681

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning

 

 

 

 

 

 

 

 

 

 

 

  of period

740

 

9,998

 

818

 

7,261

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

681

 

880

 

681

 

880

 

 

681

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow information :

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for :

 

 

 

 

 

 

 

 

 

 

 

Income taxes

-

 

-

 

-

 

-

 

 

-

 

Interest

-

 

-

 

-

 

-

 

 

-

 





See accompanying notes to condensed financial statements.




- 5 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





1.

NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES


Corporate information


DNA Systems, Inc. (the “Company”) was incorporated in the State of Nevada on October 25, 2007 for the purpose of exploring new business opportunities. The Company is a development stage company and has not yet generated any significant revenue from its operations.


On April 11, 2008, the Company entered into an agreement with DNA Financial Systems (HK) Limited (“DNAF Limited”), a Hong Kong corporation founded in 2005, pursuant to which the Company agreed to provide venues for DNAF Limited to organize conferences, seminars, corporate trainings and programs in line with professional events.


Continuance of operations


These financial statements are prepared on a going concern basis, which has considered the realization of assets and satisfaction of liabilities in the Company’s normal course of business. As of October 31, 2009, the Company had cash and cash equivalents of US$681, working capital deficit and stockholders’ deficit of US$99,357 and accumulated deficit during the development stage of US$109,001 respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern.


Management plans on the continuation of the Company as a going concern include financing the Company’s existing and future operations through additional issuance of common stock and/or advances from the major stockholder and seeking for profitable business opportunities. However, the Company has no assurance with respect to these plans. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.


Basis of preparation


The accompanying condensed financial statements are unaudited.  These condensed financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with the generally accepted accounting principles in the United States (“U.S. GAAP”) have been omitted pursuant to such SEC rules and regulations; nevertheless, the Company believes that the disclosures are adequate to make the information presented not misleading.  These condensed financial statements and the notes hereto should be read in conjunction with the financial statements and notes thereto included in the Company’s financial report for the year ended April 30, 2009.


In the opinion of the management of the Company, the unaudited condensed financial statements for the interim periods presented include all adjustments, including normal recurring adjustments, necessary to fairly present the results of such interim periods and the financial position as of the end of the said periods.  The results of operations for the interim periods are not necessarily indicative of the results for the full year.




- 6 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





1.

NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONT’D)


Cash and cash equivalents


Cash equivalents comprise highly liquid investments with original maturity of three months or less.  As of October 31, 2009, cash equivalents consisted of bank balance of US$196 and cash on hand of US$485.


Concentration of risk


The Company keeps cash in Hong Kong dollar (“HKD”) and maintains a HKD savings account with a commercial bank in Hong Kong, which are financial instruments that are potentially subject to concentration of credit risk. During the reporting periods, the Company did not engage in any hedging activities.


Income taxes


The Company accounts for income tax in accordance with ASC 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred income taxes are recognized for all significant temporary differences between tax and financial statement bases of assets and liabilities. A valuation allowance is recognized on deferred tax assets when it is more likely than not that these deferred tax assets will not be realized.


Foreign currency translation


The Company kept cash and cash equivalents and incurred expenses in HKD during the reporting periods and thus HKD is considered to be the Company’s functional currency. Transactions denominated in currencies other than HKD are translated into HKD at the applicable rates of exchange prevailing at the dates of the transactions. Monetary assets and liabilities denominated in other currencies are translated into HKD at the rates of exchange prevailing at the balance sheet date. Exchange gains and losses are included in the determination of net loss.


For financial reporting purposes, HKD has been translated into United States dollars (“US$”) as the reporting currency. Assets and liabilities are translated into US$ at the exchange rate in effect at the period end. Income and expenses are translated at average exchange rate prevailing during the period. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ deficit as “Accumulated other comprehensive income (loss)”. Gains and losses resulting from foreign currency translation are included in other comprehensive income (loss).


Conversion of amounts from HKD into US$ has been made at the exchange rate of US$1.00 for HKD7.7504 as of October 31, 2009.








- 7 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





1.

NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONT’D)


Use of estimates


The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in these financial statements and the accompanying notes during the reporting periods.  Actual results could differ from those estimates.


Fair values of financial instruments


The Company’s financial instruments include cash and cash equivalents, accrued audit fee and amount due to a stockholder.  Management of the Company does not believe that the Company is subject to significant interest, currency or credit risks arising from these financial instruments.  The respective carrying values of these financial instruments approximate their fair values since they are short-term in nature or they are receivable or payable on demand.


Recently issued accounting pronouncements


FASB Accounting Standards Codification (Accounting Standards Update “ASU” No. 2009-1)


In June 2009, the Financial Accounting Standard Board (“FASB”) approved its Accounting Standards Codification (“Codification”) as the single source of authoritative United States accounting and reporting standards applicable for all non-governmental entities, with the exception of the SEC and its staff. The Codification is effective for interim or annual financial periods ending after September 15, 2009 and impacts the Company’s financial statements as all future references to authoritative accounting literature will be referenced in accordance with the Codification. There have been no changes to the content of the Company’s financial statements or disclosures as a result of implementing the Codification.


As a result of the Company’s implementation of the Codification during the current quarter, previous references to new accounting standards and literature are no longer applicable. In these financial statements, the Company will provide reference to both new and old guidance to assist in understanding the impacts of recently adopted accounting literature, particularly for guidance adopted since the beginning of the current fiscal year but prior to the Codification.


Noncontrolling Interests (Included in amended Topic ASC 810 “Consolidation”, previously SFAS No. 160 “Noncontrolling Interests in Consolidated Financial Statements”, an amendment of ARB No. 51)


The amended topic establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. The management is in the process of evaluating the impact of adopting this amended topic on the Company’s financial statements.




- 8 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





1.

NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONT’D)


Recently issued accounting pronouncements (cont’d)


Business Combinations (Included in amended Topic ASC 805 “Business Combinations”, previously SFAS No. 141(R))


This ASC guidance addresses the accounting and disclosure for identifiable assets acquired, liabilities assumed, and noncontrolling interests in a business combination. The management is in the process of evaluating the impact of adopting this amended topic on the Company’s financial statements.


Intangibles - Goodwill and Other (Included in amended Topic ASC 350, previously FASB Staff Position (“FSP”) No. 142-3 “Determination of the Useful Life of Intangible Assets”)


The amended topic amends the factors an entity should consider in developing renewal or extension assumptions used in determining the useful life of recognized intangible assets. This new guidance applies prospectively to intangible assets that are acquired individually or with a group of other assets in business combinations and asset acquisitions.  The amended topic is effective for financial statements issued for fiscal years and interim periods beginning after December 15, 2008. Early adoption is prohibited. The adoption of this amended topic has no material effect on the Company's financial statements.


Business Combinations (Included in amended Topic ASC 805, previously FSP No. 141R-1 “Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies”)


Amended topic ASC 805 amends the requirements for the provisions for the initial recognition and measurement, subsequent measurement and accounting, and disclosures for assets and liabilities arising from contingencies in business combinations. The amended topic eliminates the distinction between contractual and non-contractual contingencies, including the initial recognition and measurement criteria and instead carries forward most of the provisions for acquired contingencies. The amended topic is effective for contingent assets and contingent liabilities acquired from business combinations for which the acquisition data is on or as of December 15, 2008. The adoption of this amended topic has no material effect on the Company's financial statements.


Fair Value Measurements and Disclosures (Included in amended Topic ASC 820, previously FSP No. 157-4 “Determining Whether a Market is Not Active and a Transaction Is Not Distressed”)


The amended topic clarifies when markets are illiquid or that market pricing may not actually reflect the “real” value of an asset. If a market is determined to be inactive and market price is reflective of a distressed price then an alternative method of pricing can be used, such as a present value technique to estimate fair value. The amended topic identifies factors to be considered when determining whether or not a market is inactive. The amended topic is effective for interim and annual periods ending after June 15, 2009, with early adoption permitted for periods ending after March 15, 2009 and shall be applied prospectively. The adoption of this amended topic has no material effect on the Company's financial statements.




- 9 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





1.

NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONT’D)


Recently issued accounting pronouncements (cont’d)


Investments - Debt and Equity Securities - Overall - Transition and Open Effective Date Information (Included in amended Topic ASC 320, previously FSP No. 115-2 and SFAS No. 124-2 “Recognition and Presentation of Other-Than-Temporary Impairments”)


The amended topic amends the other-than-temporary impairment guidance in U.S. GAAP for debt securities through increased consistency in the timing of impairment recognition and enhanced disclosures related to the credit and noncredit components of impaired debt securities that are not expected to be sold. In addition, increased disclosures are required for both debt and equity securities regarding expected cash flows, credit losses, and securities with unrealized losses. The adoption of this amended topic has no material impact on the Company’s financial statements.


Subsequent Events (Included in amended Topic ASC 855 “Subsequent Events”, previously SFAS No. 165)


The amended topic establishes accounting and disclosure requirements for subsequent events. The amended topic details the period after the balance sheet date during which the Company should evaluate events or transactions that occur for potential recognition or disclosure in the financial statements, the circumstances under which the Company should recognize events or transactions occurring after the balance sheet date in its financial statements and the required disclosures for such events. The Company adopted this amended topic effective June 1, 2009.


Accounting for Transfers of Financial Assets (Included in amended Topic ASC 860 “Transfers and Servicing”, previously SFAS No. 166 “Accounting for Transfers of Financial Assets - an Amendment of FASB Statement No. 140”)


The amended topic addresses information a reporting entity provides in its financial statements about the transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor’s continuing involvement in transferred financial assets. Also, the amended topic removes the concept of a qualifying special purpose entity, limits the circumstances in which a transferor derecognizes a portion or component of a financial asset, defines participating interest and enhances the information provided to financial statement users to provide greater transparency. The amended topic is effective for the first annual reporting period beginning after November 15, 2009 and will be effective for us as of May 1, 2010. The management is in the process of evaluating the impact of adopting this amended topic on the Company’s financial statements.







- 10 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





1.

NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (CONT’D)


Recently issued accounting pronouncements (cont’d)


Consolidation of Variable Interest Entities - Amended (Included in amended Topic ASC 810 “Consolidation”, previously SFAS 167 “Amendments to FASB Interpretation No. 46(R)”)


The amended topic require an enterprise to perform an analysis to determine the primary beneficiary of a variable interest entity; to require ongoing reassessments of whether an enterprise is the primary beneficiary of a variable interest entity and to eliminate the quantitative approach previously required for determining the primary beneficiary of a variable interest entity. The amended topic also requires enhanced disclosures that will provide users of financial statements with more transparent information about an enterprise’s involvement in a variable interest entity. The amended topic is effective for the first annual reporting period beginning after November 15, 2009 and will be effective for us as of May 1, 2010. The management is in the process of evaluating the impact of adopting this amended topic on the Company’s financial statements.


In August 2009, the FASB issued ASU No. 2009-05, an update to ASC 820 “Fair Value Measurements and Disclosures”. This update provides amendments to reduce potential ambiguity in financial reporting when measuring the fair value of liabilities. Among other provisions, this update provides clarification that in circumstances in which a quoted price in an active market for the identical liability is not available, a reporting entity is required to measure fair value using one or more of the valuation techniques described in ASU No. 2009-05. ASU No. 2009-05 will become effective for the Company’s interim financial statements for the quarter ending January 1, 2010. The management is in the process of evaluating the impact of adopting this ASU on the Company’s financial statements.


In October 2009, the FASB issued ASU No. 2009-13 “Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements – A Consensus of the FASB Emerging Issues Task Force”. This update provides application guidance on whether multiple deliverables exist, how the deliverables should be separated and how the consideration should be allocated to one or more units of accounting. This update establishes a selling price hierarchy for determining the selling price of a deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. The Company will be required to apply this guidance prospectively for revenue arrangements entered into a materially modified after January 1, 2011; however, earlier application is permitted. The management is in the process of evaluating the impact of adopting this ASU on the Company’s financial statements.





- 11 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





2.

INCOME TAXES


A reconciliation of income taxes at statutory rate in the United States is as follows :-


 

Six months

 

 

Cumulative

 

 

ended October 31,

 

 

total since

 

 

2009

 

2008

 

 

inception

 

 

(Unaudited)

 

(Unaudited)

 

 

(Unaudited)

 

 

US$

 

US$

 

 

US$

 

 

 

 

 

 

 

 

 

Loss before income taxes

(68,911

)

(9,909

)

 

(109,001

)

 

 

 

 

 

 

 

 

Expected benefit at statutory rate of 15%

(10,336

)

(1,486

)

 

(16,350

)

Valuation allowance

10,336

 

1,486

 

 

16,350

 

 

 

 

 

 

 

 

 

Income taxes

-

 

-

 

 

-

 


Recognized deferred income tax assets is as follows :-


 

 

 

As of

 

 

As of

 

 

 

 

October 31,

 

 

April 30,

 

 

 

 

2009

 

 

2009

 

 

 

 

(Unaudited)

 

 

 

 

 

 

 

US$

 

 

US$

 

 

 

 

 

 

 

 

 

Operating losses available for future periods

 

 

16,350

 

 

6,014

 

Valuation allowance

 

 

(16,350

)

 

(6,014

)

 

 

 

 

 

 

 

 

 

 

 

-

 

 

-

 


As of October 31, 2009, the Company had incurred operating losses of US$109,001 which, if unutilized, will expire through to 2029.  Future tax benefits arising as a result of these losses have been offset by a valuation allowance.



3.

NET LOSS PER SHARE


During the reporting periods, the Company did not have any dilutive instruments. Accordingly, the reported basic and diluted loss per share is the same.



4.

COMMON STOCK


The Company was incorporated on October 25, 2007 with authorized capital of 65,000,000 shares of common stock of US$0.001 par value. On December 7, 2007, 8,500,000 shares of common stock of US$0.001 par value totalling US$8,500 were issued for cash.







- 12 -



DNA SYSTEMS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2009 AND 2008

AND FROM INCEPTION ON OCTOBER 25, 2007 THROUGH OCTOBER 31, 2009





5.

STOCK INCENTIVE PLAN


The Company has not established any stock incentive plan since its incorporation.



6.

COMMITMENTS AND CONTINGENCIES


The Company entered into a sub-lease agreement for the provision of general administrative services and office premises by a related company on May 1, 2009 for a term of one year at a monthly rental of US$2,580. The expected payment as of October 31, 2009 was US$15,480, which will fall due within the next year.  The related company is controlled by the Company’s director.



7.

RELATED PARTY TRANSACTIONS


The majority stockholder, who is also the director, advanced US$95,886 to the Company to finance its working capital as of October 31, 2009.  The advance is interest-free, unsecured and repayable on demand.


The Company paid management fee of US$23,200 to a related company for the provision of general administrative services and office premises during the period from inception on October 25, 2007 through October 31, 2009.  The related company is controlled by the Company’s director.



8.

SUBSEQUENT EVENTS


The Company has evaluated all subsequent events through December 15, 2009, the date these financial statements were issued, and determined that there were no subsequent events or transactions that required recognition or disclosure in the financial statements.























- 13 -


ITEM 2.

 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


Special Note of Caution Regarding Forward Looking Statements


CERTAIN STATEMENTS IN THIS REPORT INCLUDE FORWARD-LOOKING STATEMENTS THAT INCLUDE RISKS AND UNCERTAINTIES. WE USE WORDS SUCH AS "ANTICIPATES," "BELIEVES," "PLANS," "EXPECTS," "FUTURE," "INTENDS" AND SIMILAR EXPRESSIONS TO IDENTIFY SUCH FORWARD-LOOKING STATEMENTS. THIS FORM ALSO CONTAINS FORWARD-LOOKING STATEMENTS ATTRIBUTED TO CERTAIN THIRD PARTIES RELATING TO THEIR ESTIMATES REGARDING THE OPERATION AND GROWTH OF OUR BUSINESS AND SPENDING. YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH APPLY ONLY AS OF THE DATE HEREOF. WE HAVE BASED THESE FORWARD-LOOKING STATEMENTS ON OUR CURRENT EXPECTATIONS AND PROJECTIONS ABOUT FUTURE EVENTS. OUR ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE DISCUSSED IN THIS REPORT.  OUR ABILITY TO GENERATE REVENUE IS SUBJECT TO SUBSTANTIAL RISKS.


Overview


DNA Systems, Inc. was incorporated in the State of Nevada on October 25, 2007.  Our business operations are oriented towards providing event organizing services to business partners. Our overall objective is to create an event organizing business by building a corporate image as a reliable, trustworthy partner that provides high quality event planning and organizing service to our clients.

On April 11, 2008, DNAS entered into an agreement (the “Agreement”) with DNA Financial Systems (HK) Limited (“DNAF Limited”), a Hong Kong corporation founded in 2005, pursuant to which DNAS agreed to provide venues for DNAF Limited to organize conferences, seminars, corporate trainings and programs in line with professional events; a copy of the Agreement was filed as Exhibit 10.1 to the Company’s registration statement on Form S-1 which was filed with the Securities and Exchange Commission (the “SEC”) on July 31, 2008, and is hereby incorporated by reference. Initially, we will provide the conference room located at our executive office as the venue for the professional events of DNAF Limited.  

Under the Agreement, DNAS will provide a comprehensive service for special promotions, business and marketing events. Our team of professionals will handle any event from concept to realization and will address DNAF Limited’s needs and desires, with regard to the venue setting, seating, decorations, refreshments and menus. Furthermore, pursuant to the Agreement, we will facilitate the time schedules and event flow and will serve as a point of contact for the site staff and participants. As stated in the Agreement, DNAF Limited shall pay us for the services rendered. The fees for the services that we provide are dependent upon the size, type and duration of the event. The fees shall be paid on the first of the month following the month in which the event was organized by us.

Our president and director, Mr. Wilson Cheung, has several contacts within the Hong Kong business community which we believe will assist us in developing our business operations. Mr. Cheung plans to contact various representatives within the Hong Kong business community who are interested in organizing corporate events, however there is no assurance that we will achieve or sustain profitability on an annual or quarterly basis.

Plan of Operations in the next 12 months


During the next twelve months, the Company expects to continue its efforts to provide event organizing services to business partners.  Additionally, as the Company has minimal cash on hand, in an effort to raise additional funds, on July 31, 2008, the Company filed a registration statement with the SEC for the purpose of registering 200,000 shares of its common stock. The registration statement was


- 14 -


declared effective by the SEC on September 10, 2008. The Company is planning to raise additional capital through the sale of 200,000 shares common stock in the next 12 months as its registration statement has been declared effective by the SEC. Through the sale of 200,000 shares of common stock at a price of $0.50 per share, it is expected that the Company will raise an aggregate of $100,000 for operating expenses and business expansion. We plan to use the proceeds, if any, from the offering to develop our business and acquire equipment to improve our efficiency.  


The Company plans to allocate 30% of any proceeds received to cover the expenses incurred in the offering. If the offering is 30% or less subscribed, all proceeds will be used to pay the expenses of the offering. The remaining proceeds received from the offering will be used for working capital and future administrative expenses and business development.


Funds allocated to working capital are intended to be used for hiring additional employees in the coming 12 months. They will be responsible to organize conferences, seminar, information sessions and corporate training for the potential clients. If we do not obtain enough funds from this offering, we may hire only one marketing professional to assist DNAS’s CEO, Ms. Vivian Poon.


Funds allocated to business development are intended to be used to prepare marketing materials for us to locate new business partners. We hope to build up our corporate reputation and align ourselves with additional business partners to provide our event organizing services to them. The funds allocated to administrative expenses are intended to be used for indirect expenses to maintain the daily operation of the business, such as travel expenses, stationary and postage expenses, and utility expenses.


Management plans to temporarily advance capital to maintain normal operations. Management has agreed to provide temporary financing to the Company, but is not contractually obligated to do so. If we fail to raise additional funding, we may have to delay, scale back or discontinue some or all of our operations.


We have no real property and currently operate from office space provided by Easterly Financial Investment Limited. Since May 1, 2008, the Company has paid Easterly a management fee of US$645 for its provision of general administrative services and office premises. The Company will continue to be stationed at Easterly which is controlled by the President, and will continue to pay a monthly management fee of approximately US$645 (equivalent to HK$5,000) to the related company for the provision of general administrative services and office premises.  It is expected that the Company will not purchase any property in the coming 12 months.


Results of Operations


The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our results of operation and financial condition for the fiscal period ended October 31, 2009. The following discussion should be read in conjunction with the Financial Statements and related Notes appearing elsewhere in this Form 10-Q.  Our financial statements are stated in US Dollars and are prepared in accordance with generally accepted accounting principals of the United States (“GAAP”).


Results of Operation for DNA Systems, Inc. for the three Months Ended October 31, 2009 Compared to the three Months Ended October 31, 2008.


Revenue


Revenue.  During the three month period ended October 31, 2009, the Company had revenues of $nil as compared to revenues of $nil during the three month period ended October 31, 2008. The fact that the Company did not experience any revenue during the three month period ended October 31, 2009 was attributable to the fact that the Company did not provide any event planning services during the three months ended October 31, 2009.


- 15 -



Expenses


Expenses.  During the three month period ended October 31, 2009, the Company had operating expenses of $22,982 as compared to expenses of $8,986 during the three month period ended October 31, 2008, an increase of $13,996. The increase in expenses experienced by the Company was primarily attributable to increases in operating expenses, the exploration of new business opportunities, meeting with potential customers, and locating business partners.


Net Loss


­Net Loss.  The Company had a net loss of $22,982 for the three month period ended October 31, 2009 as compared to net loss of $8,986 for the three month period ended October 31, 2008, a change of $13,996.  The increase in net loss experienced by the Company was primarily attributable to increases in expenses.


Results of Operation for DNA Systems, Inc. for the Six Months Ended October 31, 2009 Compared to the Six Months Ended October 31, 2008.


Revenue


Revenue. During the six month period ended October 31, 2009, the Company had revenues of $nil as compared to revenues of $6,407 during the six month period ended October 31, 2008, a decrease of $6,407. The decrease in revenue experienced by the Company was attributable to the fact that the Company did not provide any event planning services during the six months ended October 31, 2009.


Expenses


Expenses.  During the six month period ended October 31, 2009, the Company had operating expenses of $68,911 as compared to expenses of $16,316 during the six month period ended October 31, 2008, an increase of $52,595. The increase in expenses experienced by the Company was primarily attributable to increases in operating expenses, the exploration of new business opportunities, meeting with potential customers, and locating business partners.


Net Loss


­Net Loss.  The Company had a net loss of $68,911 for the six month period ended October 31, 2009 as compared to net loss of $9,909 for the six month period ended October 31, 2008, a change of $59,002.  The increase in net loss experienced by the Company was primarily attributable to increases in expenses.


Liquidity and Capital Resources


As of October 31, 2009, our unaudited balance sheet reflects that we have total assets of $681, as compared to total assets of $818 as of April 30, 2009, a decrease of $137. As of October 31, 2009, our unaudited balance sheet reflects that we have total liabilities of $100,038, as compared to total liabilities of $32,495 as of April 30, 2009, an increase of $67,543.  As of October 31, 2009, the Company has an accumulated deficit of $109,001.  


The Company does not have sufficient assets or capital resources to pay its on-going expenses while it is seeking out business opportunities. In an effort to raise additional funds, on July 31, 2008, the Company filed a registration statement with the SEC for the purpose of registering 200,000 shares of its common stock. The registration statement was declared effective by the SEC on September 10, 2008. As of October 31, 2009, the Company had not sold any shares pursuant to the registration statement. The Company has no agreement in place with its stockholder or other persons to pay


- 16 -


expenses on its behalf, but it is currently anticipated that the Company will rely on loans from the stockholder, Mr. Wilson Cheung, to pay any daily operating expenses prior to any fund raising exercise. The Company anticipates that this arrangement will not change until the Company is able to enough generate enough revenue to cover the Company’s operating expenses.


Off Balance Sheet Arrangements


The Company does not have any off-balance sheet arrangements.


ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.


Not Applicable


ITEM 4T.

CONTROLS AND PROCEDURES.


Disclosure Controls and Procedures


We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.


As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures.  Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are designed to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized and reported within the time periods specified.  Our principal executive officer and principal financial officer also concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.  


Changes in Internal Control over Financial Reporting


There was no change in the Company's internal control over financial reporting during the quarter ended October 31, 2009, that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.


PART II – OTHER INFORMATION


ITEM 1.

LEGAL PROCEEDINGS.


The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director,


- 17 -


officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.


ITEM 1A. RISK FACTORS.


Not Applicable.


ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.


None.


ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.


None.


ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.


None


ITEM 5.    

OTHER INFORMATION.


None.


ITEM 6.

EXHIBITS.


The following exhibits are filed herewith:


3.1

Articles of Incorporation (herein incorporated by reference from Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2008).


3.2

Bylaws (herein incorporated by reference from Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2008).


10.1

Contract with DNA Financial Systems (HK) Limited signed on April 11, 2008 (herein incorporated by reference from Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 31, 2008).


31.1*

Certifications pursuant to Rule 13a-15(a) or 15d-15(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


31.2*

Certifications pursuant to Rule 13a-15(a) or 15d-15(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


32.1*

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2*

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


* Filed Herewith



- 18 -





SIGNATURES


In accordance with Section 12 of the Securities Exchange Act of 1934, the registrant caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DNA SYSTEMS, INC.


By:  /s/ Wilson Cheung

Wilson Cheung, President and Director

Date: December 15, 2009  


In accordance with Section 13 or 15(d) of the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:


By:  /s/ Wilson Cheung

Wilson Cheung, Principal Executive Officer

Date: December 15, 2009  


By:  /s/ Wilson Cheung

Wilson Cheung, Principal Financial Officer

Date: December 15, 2009  








- 19 -